Search clinical trials for: AMG 404

Total 5234 results

Amgen

Completed

Single and Multiple Ascending Dose Study of AMG 133 in Participants With Obesity

Obesity

United States
Amgen

Terminated

Single and Multiple Ascending Dose Study of AMG 171 in Subjects With Obesity

Obesity

United States
Amgen

Completed

A Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AMG 592 in Healthy Participants

Chronic Graft-versus-host Disease (cGVHD)

United States
Amgen

Completed

P3 Study to Evaluate Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura

Idiopathic Thrombocytopenic Purpura
Amgen

Completed

AMG 529 First in Human Study

Cardiovascular

United States
Dana-Farber Cancer Institute
Massachusetts General Hospital; Brigham and Women's Hospital; Amgen; H. Lee Moffitt...

Completed

AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors

Neuroendocrine Tumor | Carcinoid Tumor | Pancreatic Neuroendocrine Tumor

United States
Amgen

Completed

Study to Assess Fixed Dosing of AMG 223 in Subjects With Chronic Kidney Disease on Hemodialysis With Hyperphosphatemia

End Stage Renal Disease | Chronic Kidney Disease | Kidney Disease | Hyperphosphatemic
Amgen

Completed

Safety, Tolerability, and Pharcodynamics of AMG 853 in Adolescents With Asthma

Asthma
Amgen

Completed

A First-in-human Study Evaluating AMG 167 in Healthy Men and Postmenopausal Women

Osteopenia
Seoul National University Hospital
Ministry of Food and Drug Safety, Korea

Completed

Pharmacokinetic-pharmacodynamic Analysis of Sugammadex for Conventional Reversal in Children

Anesthesia, General | Neuromuscular Blockade

Korea, Republic of
Matias Vested

Not yet recruiting

Neuromuscular Monitoring in Children (6 Months - 2 Years) With Electromyography and Acceleromyography

Neuromuscular Blockade

Denmark
Cytokinetics

Withdrawn

Omecamtiv Mecarbil Post-trial Access Study

Chronic Heart Failure With Reduced Ejection Fraction
Amgen

Completed

A Single-dose Study in Paediatric Patients Aged 2 to Less Than 18 Years With Secondary Hyperparathyroidism (sHPT) Receiving Haemodialysis

Chronic Kidney Disease, Secondary Hyperparathyroidism

Belgium, United States, Germany, Poland, United Kingdom, Lithuania
Amgen

Completed

Safety Study of AMG 557 in Subjects With Lupus Arthritis

Lupus Arthritis, Systemic Lupus Erythematosus

United States, Taiwan, Germany, Denmark, Australia, United Kingdom, Malaysia, France
M.D. Anderson Cancer Center
Amgen

Withdrawn

AMG 208 Tumor Microenvironment in Metastatic Castration Resistant Prostate Cancer (mCRPC)

Prostate Cancer

United States
Amgen

Terminated

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 557 in Adults With Psoriasis

Psoriasis

United States
Amgen

Completed

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 811 in Subjects With Psoriasis

Psoriasis

New Zealand, Australia
Amgen

Completed

Treatment for Patients With Osteoarthritis (OA)

Osteoarthritis
Amgen

Recruiting

A Phase 1/2 Study of AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors

MTAP-null Non-Small-Cell Lung Cancer | MTAP-null Solid Tumors

United States, Australia
Amgen

Recruiting

Single and Multiple Ascending Dose Study to Evaluate AMG 786 in Healthy Participants and Participants With Obesity

Obesity

United States
Amgen

Completed

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Olpasiran in Chinese Participants With Elevated Serum Lipoprotein(a)

Elevated Serum Lipoprotein(a)

Hong Kong
Amgen

Completed

A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Various Degrees of Hepatic Impairment

Hepatic Impairment

United States
Amgen

Terminated

Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

United States, Australia, Germany
Amgen

Completed

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of AMG 592 in Healthy Japanese Participants

Chronic Graft-versus-Host Disease (cGVHD)

Australia
Amgen

Completed

AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Prior to Splenectomy

Thrombocytopenia | Idiopathic Thrombocytopenic Purpura
Amgen

Completed

AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splenectomy

Thrombocytopenia | Idiopathic Thrombocytopenic Purpura
Amgen

Completed

Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease

Type II Refractory Celiac Disease (RCD-II) | In-situ Small Bowel T-cell Lymphoma

Spain, United States, Finland, France, Netherlands
Amgen

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 282 in Healthy Subjects and Subjects With Chronic Rhinosinusitis With Nasal Polyps

Chronic Rhinosinusitis With Nasal Polyps

United States
Amgen

Terminated

Study to Evaluate the Safety, Tolerability, and Action of AMG 357 in Females With Rheumatoid Arthritis

Rheumatoid Arthritis

United States
Amgen

Completed

Single-ascending Dose Study With a Food-Effect Cohort to Evaluate AMG 581 (FIH)

Schizophrenia or Schizoaffective Disorder

United States
Amgen

Terminated

20101299: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms

Schizophrenia

United States, Canada, Spain, Australia, New Zealand, Russian Federation, Singapore
Amgen

Completed

A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of Single Dose of AMG 623 in Subjects With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
Amgen

Completed

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), Food Effect of AMG 357 in Healthy Subjects

Inflammatory Disease

New Zealand
Amgen

Terminated

20110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms (Study 165)

Schizophrenia

United States, France, United Kingdom, Malaysia, Poland, Czech Republic
Amgen

Terminated

Investigate Effect of AMG 151 on 24-hour Ambulatory Blood Pressure & Glucose Levels in Type 2 Diabetes Mellitus Subjects

Diabetes Mellitus

United States
Amgen

Completed

Phase II Study to Evaluate the Efficacy of AMG 317

Asthma
Amgen

Completed

A Randomized, Double-blind, Placebo-controlled, Dose Response Study of AMG 162 (Denosumab) in Japanese Postmenopausal Osteoporotic Subjects

Osteoporosis
NantCell, Inc.

Terminated

QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors

Sarcoma | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Metastatic Cancer | Solid Tumors | Locally Advanced
Jiangsu Kanion Pharmaceutical Co., Ltd
Beijing Bionovo Medicine Development Co., Ltd.

Completed

A Pilot Study for Ginkgolides Meglumine Injection Skin Testing.

Allergy

China
Amgen

Terminated

Safety and Efficacy of Efavaleukin Alfa in Subjects With Steroid Refractory Chronic Graft Versus Host Disease

Chronic Graft Versus Host Disease cGVHD

United States, Japan, France, Belgium
Amgen

Completed

Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)

Thrombocytopenic Purpura
Boehringer Ingelheim

Completed

Phase I Dose Escalation of i.v. BI 836909 Monotherapy in Last Line Multiple Myeloma Patients

Multiple Myeloma

Germany, France
Cytokinetics

Withdrawn

Pharmacokinetic Study of Omecamtiv Mecarbil in Heart Failure Patients

Heart Failure
Amgen

Completed

Abrilumab (AMG 181) in Adults With Moderate to Severe Ulcerative Colitis

Ulcerative Colitis

United States, Belgium, Canada, Denmark, Italy, Hungary, Germany, Switzerland, Netherlands, Australia, Russian Federation, Austria, France, United Kingdom, Czechia, Greece, Poland, Estonia, Latvia, Norway
Amgen

Completed

Abrilumab (AMG 181) in Adults With Moderate to Severe Crohn's Disease

Crohn's Disease

United States, Canada, Denmark, Belgium, Hungary, Switzerland, Netherlands, Austria, Czechia, France, United Kingdom, Germany
Amgen

Completed

Evaluating the Safety of Long Term Dosing of Romiplostim (Formerly AMG 531) in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes | Thrombocytopenia | MDS | Hematology
Amgen

Completed

Safety and Efficacy Study of Romiplostim (AMG 531) to Treat ITP in Pediatric Subjects

Idiopathic Thrombocytopenic Purpura | Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) | Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Amgen

Completed

Open Label Extension Study of Romiplostim (AMG 531) in Thrombocytopenic Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

Thrombocytopenia | Idiopathic Thrombocytopenic Purpura
Seoul National University Hospital
Ministry of Food and Drug Safety, Korea

Completed

Pharmacokinetic-pharmacodynamic Analysis of Sugammadex in Children

Anesthesia, General | Neuromuscular Blockade

Korea, Republic of
AstraZeneca
Parexel

Recruiting

Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Severe Asthma in the United States (PASSAGE)

Asthma

United States

3

Subscribe